More than 90% of the PRCA cases were in patients treated with epoetin-α (Eprex; Johnson & Johnson, New Brunswick, NJ, USA), and almost all patients had chronic kidney disease and received epoetin via subcutaneous (SC) injection [2, 3]. This evidence concerns the gene EPO and pure red-cell aplasia.